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Summary
BACKGROUND AND AIM: Wilson’s disease is an inherit-
ed disorder of hepatic copper metabolism, leading to the
accumulation of copper in the liver as well as the brain,
cornea and other organs. Here, we describe the adult cas-
es of hepatic Wilson’s disease diagnosed at the Division of
Gastroenterology and Hepatology of the University Hospi-
tal Lausanne, Switzerland between September 2004 and
August 2016.
METHODS: Clinical manifestations, results of diagnostic
tests, management and outcomes of adult patients with
hepatic Wilson’s disease were assessed based on stan-
dardised medical records. In addition, liver histology was
reviewed and the lesional patterns were recorded.
RESULTS: Ten new adult cases of hepatic Wilson’s dis-
ease were diagnosed in our centre between September
2004 and August 2016. Male to female ratio was 1:1 and
median age at diagnosis was 26 (range 18–56) years.
Four patients presented with acute liver failure, four with
persistently elevated liver function tests, and two with de-
compensated cirrhosis; none had neurological manifes-
tations. Only one patient had a Kayser-Fleischer corneal
ring. Median ceruloplasmin level at diagnosis was 0.13
(range <0.03–0.30) g/l, median 24-hour urinary copper ex-
cretion was 2.8 (range 0.3–77.3) μmol, and median he-
patic copper concentration was 789 (range 284–1677) μg/
g. At least one mutation in the ATP7B gene was iden-
tified in eight patients. Allelic frequency of the common
H1069Q mutation was 19%. Leipzig score was ≥5 in all
patients. Three patients presenting with acute liver failure
and the two with decompensated cirrhosis underwent suc-
cessful liver transplantation. One patient with acute liver
failure recovered under chelation therapy, as predicted by
a Dhawan score <11. D-penicillamine was used as first-
line chelator treatment, with a subsequent switch to trien-
tine due to adverse effects in three out of six patients.
CONCLUSIONS: The clinical presentation of hepatic Wil-
son’s disease is highly variable. Three out of 10 patients
were diagnosed at an age >35 years. A high index of sus-
picion in clinically compatible situations is key.
Keywords: acute liver failure, ATP7B, cirrhosis, chelator
treatment, copper, Leipzig score, liver disease, liver trans-
plantation
Introduction
Wilson’s disease is a rare, autosomal-recessive, inherited
disorder of hepatic copper metabolism with a worldwide
prevalence of 1:30,000 [1–4]. It is caused by mutations of
the ATP7B gene, leading to copper accumulation in hepa-
tocytes and extrahepatic organs such as the brain and the
cornea. The ATP7B gene encodes a copper-transporting P-
type adenosine triphosphatase, which is expressed in hepa-
tocytes and transports copper into the trans-Golgi network
where it is either incorporated into apo-ceruloplasmin for
the synthesis of functional ceruloplasmin or secreted into
the bile. Under normal conditions, copper homeostasis is
ensured by biliary excretion, since dietary consumption
and absorption exceed metabolic needs. Loss of ATP7B
function results in hepatic copper accumulation, leading
to liver and/or neurological damage, with a fatal outcome
possible if left untreated [1–4].
The clinical hallmark of Wilson’s disease is the combina-
tion of liver disease, neurologic symptoms and a Kayser-
Fleischer corneal ring. However, the diagnosis of Wilson’s
disease can be difficult, as clinical presentations vary wide-
ly and a Kayser-Fleischer ring is often absent, especially
in the case of predominant liver disease [5]. Determination
of intrahepatic copper content is considered the gold stan-
dard to reach a diagnosis of Wilson’s disease, but also has
certain limitations. Molecular testing for ATP7B mutations
plays a key role in the diagnosis of Wilson’s disease but is
difficult due to the length of the gene and the large number
of mutations identified so far. The most common mutation
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in Europe is H1069Q. Nevertheless, the ATP7B genotype
does not allow predictions of the natural history and sever-
ity of Wilson’s disease [1, 2].
Histology is highly variable, ranging from mild to severe
chronic hepatitis, from simple steatosis to prominent
steatohepatitis features, or showing confluent necrosis in
fulminant cases. Progressively, increasing stages of fibro-
sis as well as macronodular cirrhosis are observed. Glyco-
genated nuclei, portal inflammation and steatosis are al-
most always present, although sometimes very mild, and
there is often marked variability in nuclear size. Copper de-
position, as identified by special stains, does not rule out
the diagnosis and is not always found [6, 7].
Medical therapy with chelators (D-penicillamine or trien-
tine) or zinc prevents disease progression and the develop-
ment of hepatic and/or neurological complications. Liver
transplantation represents a curative option [8].
Here, we describe the clinical manifestations, results of di-
agnostic tests, management and outcomes of the adult pa-
tients with a new diagnosis of hepatic Wilson’s disease
made in our centre between September 2004 and August
2016. We demonstrate that the clinical presentation of he-
patic Wilson’s disease is highly variable. Thus, improved
awareness is key to the early recognition of the disease
and, therefore, its optimal management and prognosis.
Patients and methods
Study population and design
Using standardised medical records, we collected clinical,
laboratory and histological data of all patients with a new
diagnosis of Wilson’s disease made in the Division of Gas-
troenterology and Hepatology of the University Hospital
Lausanne (Centre Hospitalier Universitaire Vaudois,
CHUV) between September 2004 and August 2016. The
CHUV is a tertiary referral centre, with approximately
10,000 gastroenterology and hepatology outpatient consul-
tations per year, as well as a very active inpatient consulta-
tion service. We closely collaborate with the Geneva Uni-
versity Hospitals (Hôpitaux Universitaires de Genève) in
a joint liver transplant program. This study was approved
by the Institutional Ethics Committee of the University of
Lausanne and informed consent was obtained from the par-
ticipants.
Clinical and laboratory analyses
Diagnosis of Wilson’s disease was based on a combination
of clinical symptoms and signs, laboratory tests, including
genetic analyses, and histological evaluation. Physical ex-
amination included neurological and psychiatric evalua-
tion. Moreover, all patients were examined for the presence
of a Kayser-Fleischer ring by an expert ophthalmologist.
Standard clinical chemistry and haematological analyses
were complemented by serologic and, if appropriate, mol-
ecular testing for hepatitis A, B, C and E; determination of
autoantibodies related to autoimmune hepatitis; and mea-
surement of serum ferritin and transferrin saturation as
well as α1-antitrypsin. Abdominal ultrasound, including
Doppler evaluation, was also performed systematically.
Liver biopsies were performed either percutaneously or,
where appropriate, via the transjugular route.
The Leipzig score [9] was used to ascertain Wilson’s dis-
ease diagnosis. It comprises the following parameters:
Kayser-Fleischer ring (2 or 0 points for present or absent
respectively), neurological symptoms (2, 1 or 0 points for
severe, mild or absent respectively), serum ceruloplasmin
(2, 1 or 0 points for <0.1 g/l, 0.1–0.2 g/l or normal [>0.2 g/
l] respectively), Coombs-negative haemolytic anaemia (1
or 0 for present or absent respectively), liver copper con-
tent (2, 1 or −1 points for >250 µg/g, 50–250 µg/g or nor-
mal [<50 µg/g] respectively), urinary copper excretion (2,
1 or 0 points for >1.6 µmol/24 h, 0.8–1.6 µmol/24 h or nor-
mal [<0.8 µmol/24 h]), and ATP7B mutation analysis (4, 1
or 0 points for mutations detected on both chromosomes,
a mutation detected on one chromosome or no mutations
detected respectively). A score of four was considered di-
agnostic for Wilson’s disease.
The Dhawan score [10], based on serum bilirubin, interna-
tional normalised ratio, aspartate aminotransferase (AST),
albumin and white blood cell count, was used to determine
the prognosis and probability of survival without liver
transplantation in patients with acute liver failure. A score
≥11 predicts a high probability of death without liver trans-
plantation.
Mutation analysis
ATP7B mutation H1069Q, which is the most common Eu-
ropean mutation, was detected by PCR [11]. In the absence
of a homozygote mutation, we analysed all ATP7B exons
using amplification with published primers [12] by dena-
turing high performance liquid chromatography (WAVE
MD System Model 4000; Transgenomics, Crewe, UK). All
exons with possible mutations were Sanger sequenced us-
ing the ABI Prism 310 Genetic Analyzer (Perkin Elmer,
Norwalk, CT) until 2012 and using the 3500 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA) thereafter. For
the patients in whom we did not identify any mutation, all
exons were sequenced. Multiplex ligation-dependent probe
amplification was performed with SALSA MLPA P098 for
Wilson’s disease (MRC-Holland, Amsterdam, NL) for the
detection of large deletions.
Histological evaluation
After 24 h of formalin fixation followed by paraffin em-
bedding, biopsies were cut at 4 µm and routinely stained
with haematoxylin-eosin, Masson's trichrome, Prussian
blue, periodic acid Schiff-diastase and reticulin. The pres-
ence of inflammation, necrosis, fat, iron, architectural dis-
tortion and fibrosis was recorded. In addition, rhodanine
and orcein stains were performed in order to identify cop-
per granules and copper-binding protein respectively.
Results
Clinical features, laboratory results and the Leipzig score
at the time of presentation are summarised in table 1. Ten
adult patients were newly diagnosed with Wilson’s disease
between September 2004 and August 2016. All presented
with exclusive hepatic forms of the disease.
Clinical presentation
Five patients were women and five men. Median age at di-
agnosis was 26 years (range 18–56 years). Notably three
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patients were older than 35 years at diagnosis. Clinical
presentation was highly variable. Four patients presented
with acute liver failure, four with persistently elevated liver
function tests, and two with decompensated cirrhosis. Pa-
tient 8 is the sister of patient 3. None of the patients had
neurological manifestations. Only one patient presented a
Kayser-Fleischer corneal ring. Time from initial presenta-
tion to diagnosis varied between a few hours for patients
presenting with typical laboratory features in a context of
acute liver failure and 20 years for patient 7.
Laboratory parameters
Standard laboratory tests
Median AST at diagnosis was 122 U/l (range 32–161 U/l)
and median ALT was 90 U/l (range 40–317 U/l). AST:ALT
ratio was >1 in six patients. Median alkaline phosphatase
(ALP) was 94 U/l (range 15–253 U/l). In the cases with
acute liver failure, ALP was low in all patients and inferior
to the normal range in two; transaminases were only mildly
elevated, with an AST:ALT ratio >1 in all patients and a
ratio >2 in two (table 2).
Copper metabolism
Median serum ceruloplasmin level at diagnosis was 0.13
g/l (range <0.03–0.30 g/l); only one patient had a normal
level. Median 24-h urinary copper excretion was 2.8 μmol
(range 0.3–77.3 µmol); only one patient had a urinary cop-
per excretion <1.6 µmol/24 h. Median hepatic copper con-
tent was 789 μg/g (range, 284–1677 µg/g) and all patients
had a concentration >250 μg/g. Median non-ceruloplas-
min-bound serum copper was 365 μg/l (range 14–546 µg/
l) and it was <150 μg/l in two patients.
Genetic testing
Molecular analysis of the ATP7B gene was performed in
all patients. At least one mutation in the ATP7B gene was
identified in eight patients. Allelic frequency of the com-
mon H1069Q mutation was 19%. In patient 9, a young la-
dy presenting with the typical clinical, laboratory and his-
tological features of Wilson’s disease-related acute liver
failure, and in patient 10, a 44-year-old man presenting
with decompensated cirrhosis, no ATP7B mutation could
be identified.
Histology
The histological patterns observed in this series are sum-
marised in table 3. Five patients showed chronic hepatitis
as a predominant pattern, ranging from mild to moderate,
or even severe in one patient (fig. 1A), associated with ad-
vanced fibrosis in one and with cirrhosis in three patients.
Macrovesicular steatosis was prominent in two patients,
including one showing features of steatohepatitis with mild
fibrosis (fig. 1B). One patient had a pattern of multifo-
cal necrosis on a background of fibrosis (fig. 1C). Copper
granules and copper-binding proteins were observed in this
latter case as well as in the three patients with cirrhosis.
Glycogenated nuclei were present in all cases.
Diagnosis
The Leipzig score was ≥5 in all patients, confirming the di-
agnosis of Wilson’s disease.
Management and outcome
The treatment and outcomes of the patients are sum-
marised in table 4. All patients are alive. Of the four pa-
tients presenting with acute liver failure, three were trans-
planted with excellent outcomes. Patient 5 was treated with
a copper chelating agent and recovered without liver trans-
Table 1: Characteristics of patients with Wilson disease.
Pt Sex Age at P/D Clinical presentation Kayser-
Fleischer
ring
CP
(g/l)
S Cu
(μg/l)
24 h U Cu
(μmol)
H Cu (μg/g) APT7B mutation Leipzig score
1 F 31/37 Cirrhosis No 0.30 393 2.5 284 R969Q/R969Q 8
2 M 22/22 Acute liver failure Yes 0.13 546 60 789 H1069Q/n.i. 9
3 F 22/22 Acute liver failure No 0.11 n.a. 77.3 n.a. H1069Q/n.i. (5)
4 M 25/25 Elevated LFTs No 0.03 14 2.2 402 M645R/D1306Y 10
5 F 30/30 Acute liver failure No 0.18 433 62 1049 R616Q/A1140V 10
6 M 18/18 Elevated LFTs No 0.17 95 22 757 L979Q/n.i. 6
7 M 36/56 Elevated LFTs No <0.03 n.a. 0.3 426 T977M/A1074T 8
8 F 25/27 Elevated LFTs No 0.11 163 1.9 911 H1069Q/n.i. 6
9 F 18/18 Acute liver failure No 0.05 499 n.a. 1677 n.i. (5)
10 M 37/44 Cirrhosis No 0.17 337 2.8 852 n.i. 5
24 h U Cu = 24-hour urinary copper excretion; age at P/D = age at presentation/diagnosis; ALP = alkaline phosphatase; CP = ceruloplasmin; H Cu = intrahepatic copper content;
LFTs = liver function tests; n.a. = not available; n.i. = none identified; Pt = patient; S Cu = non-ceruloplasmin-bound serum copper. Leipzig scores in parentheses are based on
incomplete diagnostic datasets.
Table 2: Laboratory results for patients with acute liver failure.
Pt AST
(U/l)
ALT (U/l) AST:ALT Ratio ALP (U/l) Bilirubin (μmol/
l)
ALP:total bilirubin ra-
tio
INR Hb (g/l) Dhawan score
2 154 140 1.1 60 364 0.2 3.6 103 13
3 123 42 2.9 23 250 0.1 2.4 85 13
5 156 97 1.6 109 69 1.6 2.2 98 10
9 161 59 2.7 15 175 0.1 3.5 66 16
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; Hb = haemoglobin; INR = international normalised ratio. A Dhawan score ≥11
is associated with a high probability of death without liver transplantation.
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plantation, as predicted by a Dhawan score <11 (see table
2).
Of the six patients presenting with chronic forms of the
disease, four were treated with D-penicillamine and two
with zinc as first-line treatment. D-penicillamine had to be
replaced by trientine in three patients because of hemato-
logic adverse effects (predominantly neutropenia). Chela-
tion therapy did not allow for recovery of the two patients
Table 3: Histological lesional patterns.
Pt Clinical presenta-
tion
Histology
1 Cirrhosis Cirrhosis and moderate chronic
hepatitis, copper +
2 Acute liver failure Advanced fibrosis and severe
chronic hepatitis
3 Acute liver failure n.a.
4 Elevated LFTs Steatosis
5 Acute liver failure Cirrhosis and moderate chronic
hepatitis, copper +
6 Elevated LFTs Mild chronic hepatitis, no fibro-
sis
7 Elevated LFTs n.a.
8 Elevated LFTs Steatohepatitis
9 Acute liver failure Multifocal necrosis, advanced
fibrosis, copper +
10 Cirrhosis Cirrhosis and moderate chronic
hepatitis, copper +
LFTs = liver function tests; n.a. = not available; Pt = patient.
Table 4: Management and outcome of patients with Wilson’s disease.
Pt Medical treat-
ment
Liver trans-
plantation
Outcome
1 D-penicillamine →
trientine
Yes Excellent
2 D-penicillamine Yes Excellent
3 none Yes Excellent
4 Zinc acetate → D-
penicillamine
No Normal LFTs
5 D-penicillamine →
trientine
No Excellent
6 D-penicillamine No Normal LFTs
7 Zinc acetate → D-
penicillamine
No Normal LFTs
8 D-penicillamine No Normal LFTs
9 none Yes Excellent
10 D-penicillamine →
trientine
Yes Excellent
LFTs = liver function tests; Pt = patient.
who presented initially with decompensated cirrhosis, both
of whom were >35 years old at the time of diagnosis. Thus,
patients 1 and 10 underwent liver transplantation. Patient
7, in whom diagnosis was made at age 56 in the context of
persistently elevated liver function tests, stopped treatment
and is currently stable.
Discussion
Ten adult patients with hepatic Wilson’s disease were di-
agnosed in the Division of Gastroenterology and Hepatol-
ogy of the CHUV between September 2004 and August
2016. Our study underlines the challenge of establishing
Wilson’s disease diagnosis, not only because it is a rare
condition but also because the clinical, laboratory and his-
tological manifestations are highly variable. As shown in
our study, prompt recognition of the disease plays a key
role in the management of patients, as hepatic and neuro-
logical damage can develop rapidly [1–4].
In our cohort, all patients had exclusive hepatic presenta-
tion. Median age was 26 years. The oldest patient, patient
7, was 56 years old at diagnosis. Patients with Wilson’s
disease usually become symptomatic between the ages of
5 and 35 years, with earlier onset of symptoms for hepatic
disease, and neurological and psychiatric manifestations
appearing later [1, 2]. However, cases of later onset Wil-
son’s disease have been described [13, 14]. Given its high-
ly variable presentation, Wilson’s disease should be con-
sidered in any patient presenting with unclear hepatic or
neurologic disease, independently of age [14].
Four patients presented with acute liver failure and the oth-
er six with chronic forms (persistently elevated liver func-
tion tests or decompensated cirrhosis). In a retrospective
study including 30 patients with Wilson’s disease, 22 pre-
sented with chronic forms and 8 with acute liver failure,
with a mean age at diagnosis of 21 years [15]. In another
study including 163 patients with WD, 137 were sympto-
matic at diagnosis, 26 were diagnosed by family screening
and 8 presented with acute liver failure [16].
As stated above, the diagnosis of Wilson’s disease is not
always straightforward. In our patients, Wilson’s disease
was suspected in the presence of a clinical presentation and
compatible laboratory tests, and confirmed by the results
of intrahepatic copper determination and genetic analyses.
Intrahepatic copper is considered the best biochemical test
Fig. 1: Histological patterns observed in patients with Wilson’s disease. (A) Severe chronic hepatitis characterised by numerous inflam-
matory cells in the portal tracts, interface hepatitis and advanced fibrosis (patient 10, haematoxylin-eosin, × 10). Copper granules can be iden-
tified in the cytoplasm of periportal hepatocytes (insert, rhodanine stain, × 40). (B) Steatohepatitis with macrovesicular steatosis, ballooned he-
patocytes and mild inflammation and fibrosis (patient 8, haematoxylin-eosin, × 10). (C) Multifocal necrosis (patient 9, hematoxylin-eosin, × 10).
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for Wilson’s disease [1, 2]. All our patients presented with
an intrahepatic copper content >250 μg/g. Another instru-
ment that was shown to provide good diagnostic accura-
cy in the diagnosis of Wilson’s disease is the Leipzig score
[1]. It is based on clinical symptoms and signs, laboratory
tests and mutation analysis. A score >4 is considered diag-
nostic for Wilson’s disease [17]. The Leipzig score was ≥5
in all our patients.
In the cases with acute liver failure due to Wilson’s disease,
the decision to start chelation treatment or to evaluate pa-
tients for liver transplantation should not await the results
of laboratory investigations documenting disturbed copper
metabolism [18]. Indeed, Korman et al. demonstrated that
an ALP:total bilirubin ratio <4 in patients with acute liver
failure is, as an initial screening tool, highly sensitive and
specific for Wilson’s disease (94% and 96%, respectively)
[19]. Moreover, when combined with an AST:ALT ratio
>2.2, sensitivity and specificity increase up to 100%. In our
cohort, we observed that all patients with acute liver fail-
ure presented an ALP:total bilirubin ratio <4 and two of the
four had an AST:ALT ratio >2.2.
Genetic analyses revealed at least one ATP7B mutation
in eight patients. Allelic frequency of H1069Q, the most
common mutation in Europe [20], was 19%. In a retro-
spective study of 117 patients with Wilson’s disease, the
most frequent ATP7B mutation was H1069Q, with an al-
lelic frequency of 54% [21]. However, there are more than
500 reported mutations, and most patients are compound
heterozygotes. On this background, genetic analyses are
sometimes inconclusive [22].
No mutation was identified in patients 9 and 10, as de-
scribed in earlier studies [16]. One explanation could be
that genes other than ATP7B have a role in copper me-
tabolism, resulting in copper accumulation when mutated.
Moreover, mutations in introns or regulatory elements may
affect ATP7B gene expression [23]. More advances in this
area are needed.
Most of our patients presented an excellent outcome. How-
ever, the two patients who presented with decompensated
cirrhosis at the age of 37 and 44 years (patients 1 and 10 re-
spectively) did not recover on chelation therapy, indicating
that the disease was too advanced. Both were successfully
transplanted. Wilson’s disease, if treated early, has a good
prognosis, with survival rates similar to the general pop-
ulation [16, 22]. As first-line treatment, six patients were
treated with D-penicillamine and two patients with zinc.
Treatment was readjusted in five patients. Three of the six
patients (50%) treated initially with D-penicillamine devel-
oped hematologic adverse effects and had to be switched
to trientine. Adverse effects of D-penicillamine requiring a
change in therapy have been reported to occur in approx-
imately 30% of patients [24]. We did not register any sig-
nificant adverse effect of trientine.
In conclusion, Wilson’s disease is a rare but potentially fa-
tal disease that should always be included in the differen-
tial diagnosis of patients with acute or chronic liver dis-
ease. Our study underlines the variability in presentation
and the challenge in establishing a diagnosis of Wilson’s
disease in some patients. The Leipzig score was confirmed
to be very useful for this purpose. Timely diagnosis is im-
portant to avert progression of liver disease and to stratify
patients presenting with acute liver failure for liver trans-
plantation.
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